Clinical trials: Human Immunodeficiency Virus Type 1
Prevention of Infection With HIV-1
Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers
The is a blinded safety study of ibalizumab given by subcutaneous injection in sequentially increasing dose-groups of at-risk, HIV-negative, healthy volunteers.
- Trial name
- TMB-108 (NCT01292174)
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
HIV Infection
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
The purpose of this study is to determine the safety, toxicity, dosing, and antiviral effects of epigallocatechin gallate (EGCG) in capsule form (Polyphenon® E), administered orally twice daily at three different doses in…
- Trial name
- NCT01433289
- Testing
- Polyphenon E
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
HTLV-I Infections, HTLV-II Infections
Dual Algorithm Post Market Clinical Study
The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed screening assay (Abbott Prism) and non-reactive…
- Conditions
- HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2
- Trial name
- NCT03146013
- Testing
- MP Diagnostics HTLV Blot 2.4
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MP Biomedicals, LLC
HIV, HIV Infections
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons
The purpose of this study is to look at the effect of daily herpes medication, valacyclovir, on HIV levels in the blood in persons who are HIV positive and do not have oral or genital herpes.
- Trial name
- NCT01059084
- Testing
- Valacyclovir
- Sponsor
- University of Washington
HIV Infections
Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 vaccines based on chimpanzee serotypes of adenovirus expressing clade C gp140 and a CH505TF gp120 protein boost in healthy, HIV- uninfected adult…
- Trial name
- HVTN139 (NCT05182125)
- Testing
- AdC6-HIVgp140, AdC7-HIVgp140, CH505TF gp120
- Where
- 6 sites in South Africa
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Human Immunodeficiency Virus Infection
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
This study is an open-label extension of RFSP-AMDX-2010 study for those subjects who received treatment with amdoxovir (300 mg or 500 mg twice daily) for 12 weeks and benefited from it.
- Trial name
- NCT01738555
- Testing
- amdoxovir 300 mg bid, amdoxovir 500 mg bid
- Sponsor
- RFS Pharma, LLC
HIV/AIDS and Infections
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART…
- Trial name
- RHIVIERA-02 (NCT05300035)
- Testing
- Recombinant human monoclonal antibody (bNAbs)
- Where
- 17 sites in France
- Volunteers
- 69 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection, Hepatitis
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
Early identification of acute HCV infection is essential to prevent chronic infections and the long-term liver disease complications that may occur.
- Trial name
- SWIFT-C (NCT02128217)
- Testing
- Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Severe Illness, Septicaemia
Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda
BCG vaccination may have non-specific effects (NSE) i.e., additional benefits on childhood morbidity and mortality that are separate the vaccine's effect on the incidence of disseminated tuberculosis.
- Conditions
- Severe Illness, Septicaemia, Diarrhoea, Lower Respiratory Infection
- Trial name
- NCT02606526
- Testing
- BCG at birth, Control arm: Delayed BCG
- Where
- Uganda
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Makerere University
HIV-1 Infection, Neuropathic Pain
Pregabalin Trial In HIV Neuropathic Pain
This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.
- Trial name
- NCT01145417
- Testing
- pregabalin (Lyrica)
- Where
- 29 sites in United States, Colombia and 5 more
- Volunteers
- 217 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
HIV-1 Infection
Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen
During the past years the treatment of HIV-1 infection has transformed towards chronic treatment. Patients are being treated with antiretroviral drugs for many years and become older.
- Trial name
- PRADAII (NCT02566707)
- Testing
- Atazanavir, Dolutegravir, Lamivudine
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 9 people
- Sponsor
- Radboud University Medical Center
HIV, HIV -1 Infection
Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil
The goal of this study is to understand the profile of individuals who demonstrate transmitted drug resistance to Dolutegravir (DTG) among PLHIV in Brazil in terms of the subtypes of virus and other individual characteristics…
- Trial name
- ARDOL (NCT07618507)
- Testing
- TL+D antiretroviral
- Where
- 9 sites in Brazil
- Volunteers
- 777 people
- Sponsor
- Federal University of São Paulo
HIV Infections
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
This is an open-label, randomized and multi-center study to compare the efficacy and safety of continued enfuvirtide (Fuzeon) plus (+) OB therapy versus OB alone in participants with HIV-1 infection.
- Trial name
- NCT02733419
- Testing
- Enfuvirtide, Optimized background antiretroviral regimen (OB)
- Where
- 71 sites in France
- Volunteers
- 84 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada
This study looked at lipid changes in human immunodeficiency virus type 1 (HIV-1) infected patients when the nucleoside reverse transcriptase inhibitors (NRTIs) in their existing highly active antiretroviral therapy (HAART)…
- Trial name
- TOTEM (NCT00323492)
- Testing
- Truvada, Current HAART regimen
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
HIV Infections, Pregnancy
Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of HIV Type 1
The purpose of the study was to test the equivalence of a short zidovudine (ZDV) regimen as compared to a longer, ACTG-076-like, ZDV regimen in reducing the risk of mother-to-child transmission of HIV: and to assess and compare…
- Trial name
- NCT00386230
- Testing
- ZDV Short (mother)-Short (infant): Comparison of zidovudine durations, ZDV Short (mother)-Long (infant): Comparison of zidovudine durations, ZDV Long (mother)-Short (infant): Comparison of zidovudine durations
- Where
- Thailand
- Volunteers
- 1,554 people
- Sponsor
- Institut de Recherche pour le Developpement
HIV/AIDS
Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response In HIV Reservoir
A longitudinal observational study in HIV-infected subjects receiving cART addressed to explore the effect of the Tat protein and anti-Tat immunity on the formation and maintenance of HIV-1 virus reservoir.
- Trial name
- ISS OBS T-005 (NCT04263207)
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Barbara Ensoli, MD, PhD
Acquired Immunodeficiency Syndrome, HIV Infections
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
This study is to characterize the effect of cobicistat-based regimens on parameters of renal function in participants with HIV infection and who have mild to moderate renal impairment, and to assess the safety and tolerability of…
- Trial name
- NCT01363011
- Testing
- E/C/F/TDF, COBI, ATV
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
HIV Infections
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.
- Trial name
- NCT00097799
- Testing
- Tipranavir, Ritonavir
- Where
- 115 sites in United States
- Sponsor
- Boehringer Ingelheim
HIV Infections, Tuberculosis
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
Successful therapy of both tuberculosis and HIV disease share similar problems: pill burden, drug interaction, adherence challenge and toxicity.
- Trial name
- NCT00115609
- Testing
- efavirenz, tenofovir DF, emtricitabine
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections, Hiv
Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants
The purpose of the study is to test the effect of the Alere™ q HIV-1/2 Detect (diagnostic assay) on uptake of HIV testing among HIV-exposed infants and young children, and health outcomes for HIV-infected infants and young…
- Trial name
- CDC Detect (NCT03133728)
- Testing
- Alere Q Testing
- Where
- 6 sites in Zambia
- Volunteers
- 1,682 people
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.